Improved Diagnosis of Ovarian Cancer by Use of Circulating Tumor DNA as a Biomarker
NCT ID: NCT05763511
Last Updated: 2024-05-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
300 participants
OBSERVATIONAL
2022-07-01
2029-05-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
We hypothesize that measurement of ctDNA in women with suspected ovarian cancer can improve the diagnostic efficiency for preoperative differentiation between benign and malignant masses.
Specifically, we hope to determine the diagnostic efficiency of ctDNA alone and ctDNA in combination with imaging modalities (ultrasonography, MRI, PET-CT) and CA 125 for preoperative differentiation between benign and malignant adnexal masses. Based on this, we hope to develop an improved diagnostic algorithm.
The mutational profile and relation to tumour type, stage, treatment response and prognosis will be explored.
Analyses of blood and tissue samples will be used to examine the disease development and biology.
Blood samples, tumour tissue and data on imaging modalities as well as CA 125 will be collected prospectively in consecutive women referred to Aarhus University Hospital.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Predicting the Risk of Ovarian Cancer Recurrence Using Circulating Tumor DNA to Assess Residual Disease
NCT05212779
Plasma ctDNA Detection in Diagnosis of Epithelial Ovarian Cancer.
NCT03155451
Studying DNA in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer
NCT00900289
Circulating Tumor DNA Exposure in Peripheral Blood
NCT03517332
CtDNA as a Novel Biomarker of Treatment Efficacy in Patients With Ovarian Cancer
NCT05027828
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Informed consent
Exclusion Criteria
* Previous ovarian cancer diagnosis
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Aarhus University Hospital
OTHER
University of Aarhus
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ina Marie Dueholm Hjorth
Medical doctor, PhD student
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ina Marie Dueholm Hjorth, MD
Role: PRINCIPAL_INVESTIGATOR
University of Aarhus
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Gynaecology and Obstetrics, Aarhus University Hospital
Aarhus, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Ina Marie Dueholm Hjorth, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Ovarian cancer ctDNA
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.